The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer
- Ist Teil von
- The New England journal of medicine, 2022-07, Vol.387 (3), p.217-226
- Ort / Verlag
- Boston: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- Free E-Journal (出版社公開部分のみ）
- Beschreibungen/Notizen
- Among patients with triple-negative breast cancer and high expression of PD-L1, pembrolizumab plus chemotherapy resulted in longer overall survival than chemotherapy alone.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2202809Titel-ID: cdi_proquest_miscellaneous_2692071888
- Format
- –
- Schlagworte
- Apoptosis, Breast Cancer, Cancer therapies, Carboplatin, Chemotherapy, Confidence intervals, Death, Disease control, Gemcitabine, Hematology, Immunotherapy, Ligands, Lymphocytes, Macrophages, Metastases, Metastasis, Monoclonal antibodies, Nanoparticles, Oncology, Paclitaxel, PD-L1 protein, Pembrolizumab, Placebos, Statistical analysis, Targeted cancer therapy, Treatments in Oncology, Tumor cells, Tumors